# Article information:

Tranylcypromine in mind (Part I): Review of pharmacology - ScienceDirect  
<https://www.sciencedirect.com/science/article/pii/S0924977X17302523>

# Article summary:

1. Tranylcypromine (TCP) is an irreversible and nonselective MAO-A/B inhibitor at low therapeutic doses of 20 mg/day.

2. TCP has a pharmacokinetic half-life (t1/2) of only 2 h, but a very long pharmacodynamic half-life of about one week due to its irreversible MAO inhibition.

3. TCP is characterized by an exceptional pharmacology which is different to most other antidepressant drugs, and may require special evaluation of clinical efficacy and safety.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article “Tranylcypromine in mind (Part 1): Review of Pharmacology” provides a comprehensive review of the monoamine oxidase inhibitor tranylcypromine (TCP). The article presents a thorough overview of the pharmacological properties, pharmacokinetics, drug interactions, toxicology, and clinical studies related to TCP. The authors provide evidence for their claims from multiple sources including animal studies, clinical trials, and meta-analyses.

The article appears to be unbiased in its presentation of the evidence for TCP’s efficacy as an antidepressant drug. It does not appear to be promotional or partial in any way; rather it presents both the potential benefits and risks associated with using this medication. The authors also note that further research is needed in order to better understand the effects of TCP on various aspects such as its metabolites and comedication interactions.

In terms of trustworthiness and reliability, the article appears to be well researched and supported by evidence from multiple sources. However, there are some points that could have been explored more thoroughly such as possible counterarguments or alternative treatments for depression that may be more effective than TCP. Additionally, while the authors do mention potential risks associated with using this medication, they do not provide detailed information on how these risks can be minimized or avoided when taking this medication.

In conclusion, this article provides a comprehensive review of tranylcypromine (TCP), presenting both its potential benefits and risks in an unbiased manner. While it appears to be reliable overall, there are some areas where further exploration could have been done in order to provide a more complete picture of this medication’s effects on patients suffering from depression.

# Topics for further research:

* Tranylcypromine side effects
* Tranylcypromine drug interactions
* Tranylcypromine metabolism
* Alternative treatments for depression
* Tranylcypromine safety profile
* Tranylcypromine clinical trials

# Report location:

<https://www.fullpicture.app/item/31093ac3cdaa568ff598e34c7b5c13dd>